IMTX

NASDAQ 已收盘

Immatics

6.18 USD
▼-0.73-10.56%
盘后 6.30 +1.94%
2026-11-05
市值
$869.35M
市盈率
—
EPS
-1.83
股息率
—
52 周区间
6.15 – 12.41
成交量
1.28M
Beta
1.35
目标价
16.40
52W 低 6.1552W 高 12.41
价格走势

公司简介

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes Anzu-cel (IMA203), a one-time infusion PRAME cell therapy, which is in Phase 2 trial; IMA203CD8, a cell therapy produ...